Arun Rangaswami

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Determine the overall, pulmonary, structural, and biochemical response rate to selpercatinib in patients with RET fusion differentiated thyroid cancer treated with 6 months of selpercatinib prior to 131I therapy

Recruiting

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarco...

Estimated four year thoracic event free survival (tEFS) where tEFS is calculated as the time from study enrollment to thoracic cavity event. Any recurrence within the pulmonary parenchyma, involving the pleural surface or the drai...

Recruiting

Project: Every Child for Younger Patients With Cancer

The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Adva...

Will be estimated over time and considered in relationship to changes in treatment trial cohort status (activations, suspensions, terminations).

Recruiting

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusi...

The Kaplan-Meier method will be used to estimate 3-year FFS along with 80% log-minus-log transformed confidence limits for very low risk (VLR) patients.

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Child...

EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.

Recruiting

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma...

Response rates at the end of Cycle 2 will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method. Any eligible type II/III patient...

Recruiting

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinom...

Safety of ET140203 T cells as assessed by the number of adverse events (AEs) after infusion

Recruiting

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

irRECIST criteria

Recruiting

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

The primary endpoint is the complete pulmonary structural response rate to larotrectinib by modified Nies et al thyroid cancer response criteria.

Recruiting